



University at Buffalo  
The State University of New York

Department of Pharmaceutical Sciences  
School of Pharmacy and Pharmaceutical Sciences

# Population Pharmacokinetics and Pharmacodynamics (August 22-23, 2005)

## Monday, August 22, 2005

	Room	Title	Speaker
9:30–10:30 am	Cooke 508	CNS Disease Progression and Drug Action	Nick Holford
10:30–10:50 am	Cooke 508	Break	
10:50–11:50 am	Cooke 508	The Pharmacokinetics and Pharmacodynamics of Biotechnologically Derived Products: Function Follows Form	Diane Mould
12:00–1:30 pm	Cooke 508	Informal lunch and discussions with students and postdocs	
2:00–3:00 pm	Cooke 508	Models for Haematopoiesis	Nick Holford
3:00–3:20 pm	Cooke 508	Break	
3:20–4:20 pm	Cooke 508	Population Pharmacodynamic Models for Granulocyte Stimulating Factors	Diane Mould

## Tuesday, August 23, 2005

9:30–10:30 am	Cooke 508	Using Logistic Regression	Diane Mould
10:30–10:50 am	Cooke 508	Break	
10:50–11:50 am	Cooke 508	Bootstrap and Confidence Intervals	Nick Holford
12:00–1:30 pm	Cooke 540	Informal lunch and discussions with faculty	
2:00–3:00 pm	Cooke 508	Randomization and Mixture Approaches to Model Building	Nick Holford
3:00–3:20 pm	Cooke 508	Break	
3:20–4:20 pm	Cooke 508	Population Pharmacokinetic and Pharmacodynamic Analysis of Paclitaxel In Patients with Advanced Epithelial Ovarian Cancer	Diane Mould

## Workshop Leaders

### Diane R Mould, Ph.D.

Dr Mould obtained her PhD in Pharmaceutics and Pharmaceutical Chemistry at The Ohio State University in 1989. She has since spent 16 years as a pharmacokineticist in the pharmaceutical industry where she specializes in population pharmacokinetic and pharmacodynamic modeling. During this time, she has conducted population PK/PD analyses of hematopoietic agents, anti-cancer and anti-viral agents, antipsychotic and sedative/hypnotic agents. Dr Mould has also been involved in clinical trial simulation and study design in drug development for 10 years. She was a member of the Scientific Advisory Group for PharSight where she assisted in the development of their clinical trial simulation package.

She is the president of Projections Research Inc, a consulting company offering pharmacometric services to the pharmaceutical industry. She has published 17 peer-reviewed articles, 8 book chapters and has made numerous national and international presentations of advanced modeling approaches and simulation work. She currently holds a position as an adjunct professor at the University of Rhode Island at Providence and teaches a class on disease progress modeling at the National Institutes of Health.

### Nicholas HG Holford, MBCB, FRACP

Dr Holford is currently an Associate Professor in the Department of Pharmacology and Clinical Pharmacology at the University of Auckland. His research interests include population PKPD analyses of clinical trials of drugs and clinical trial simulation. He is currently developing the use of disease progress models for understanding clinical pharmacology with an emphasis on the effects of levodopa in Parkinson's Disease, drugs affecting post-menopausal bone loss, erythropoietic stimulation in cancer, and the time course of response to antidepressants.

He is a founding member of the Scientific Advisory Board for the Center for Drug Development Science (CDDS). The CDDS, formerly based at Georgetown University, Washington DC, is now an integral part of the Division of Clinical Pharmacology at the University of California at San Francisco. The CDDS is concerned with promoting research and teaching on the scientific basis of drug development.